Legacy PBM Model is Misaligned with Plan Sponsors’ Interests and Needs
How do you effectively manage and mitigate constantly rising drug costs to ensure the lifelong health of your members/patients and the continuing viability of your organization’s benefits plans? The pharmacy benefits management (PBM) industry was originally founded with the objective of solving these issues, especially to manage the inexorable rise of prescription drug costs. The problem is that traditional PBM players have been pushing a volume-focused, rebate-driven approach to pharmacy benefits care at the expense of plan sponsors and their members.
The fact is, contracts that are structured around per-claim administration fees, or those that maximize rebates, are incentivized to increase the volume of claims. A volume-driven model does not address the growing concerns around sustainable spending and making sure the most clinically appropriate therapies are provided to members/patients. In addition, increased volume causes members to pay more or take medications they don’t need. Ultimately, plan sponsors are left to pay the bills.
That traditional PBM model is so flawed that government regulators and the US Congress are moving aggressively to adopt new measures that will bring more transparency to the industry and rein in the self-dealing practices of the major PBM players.
The legacy PBM model is clearly broken, resulting in a vicious cycle of poor plan results and sub-optimal patient health outcomes.